相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The Effect of Lenalidomide on Health-Related Quality of Life in Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes: Results From the MDS-005 Study
Valeria Santini et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2018)
Sotatercept with long-term extension for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes: a phase 2, dose-ranging trial
Rami Komrokji et al.
LANCET HAEMATOLOGY (2018)
Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study
Uwe Platzbecker et al.
LANCET ONCOLOGY (2017)
A phase 3 randomized placebo-controlled trial of darbepoetin alfa in patients with anemia and lower-risk myelodysplastic syndromes
U. Platzbecker et al.
LEUKEMIA (2017)
A randomized study of pomalidomide vs placebo in persons with myeloproliferative neoplasm-associated myelofibrosis and RBC-transfusion dependence (vol 31, pg 896, 2017)
A. Tefferi et al.
LEUKEMIA (2017)
Adding molecular data to prognostic models can improve predictive power in treated patients with myelodysplastic syndromes
A. Nazha et al.
LEUKEMIA (2017)
Comparison of risk stratification tools in predicting outcomes of patients with higher-risk myelodysplastic syndromes treated with azanucleosides
A. M. Zeidan et al.
LEUKEMIA (2016)
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
Daniel A. Arber et al.
BLOOD (2016)
The efficacy of current prognostic models in predicting outcome of patients with myelodysplastic syndromes at the time of hypomethylating agent failure
Aziz Nazha et al.
HAEMATOLOGICA (2016)
Prospective international validation of the Quality of Life in Myelodysplasia Scale (QUALMS)
Gregory A. Abel et al.
HAEMATOLOGICA (2016)
Randomized Phase III Study of Lenalidomide Versus Placebo in RBC Transfusion-Dependent Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes and Ineligible for or Refractory to Erythropoiesis-Stimulating Agents
Valeria Santini et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial
Guillermo Garcia-Manero et al.
LANCET ONCOLOGY (2016)
The efficacy of current prognostic models in predicting outcome of patients with myelodysplastic syndromes at the time of hypomethylating agent failure
Aziz Nazha et al.
HAEMATOLOGICA (2016)
Prospective international validation of the Quality of Life in Myelodysplasia Scale (QUALMS)
Gregory A. Abel et al.
HAEMATOLOGICA (2016)
Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes
David P. Steensma et al.
BLOOD (2015)
Extended survival and reduced risk of AML progression in erythroid-responsive lenalidomide-treated patients with lower-risk del(5q) MDS (vol 28, pg 1033, 2014)
A. F. List et al.
LEUKEMIA (2015)
Two splice-factor mutant leukemia subgroups uncovered at the boundaries of MDS and AML using combined gene expression and DNA-methylation profiling
Erdogan Taskesen et al.
BLOOD (2014)
CpG island methylator phenotype of myelodysplastic syndrome identified through genome-wide profiling of DNA methylation and gene expression
Xiaoli Zhao et al.
BRITISH JOURNAL OF HAEMATOLOGY (2014)
Results of a Randomized, Double-Blind Study of Romiplostim Versus Placebo in Patients With Low/Intermediate-1-Risk Myelodysplastic Syndrome and Thrombocytopenia
Aristoteles Giagounidis et al.
CANCER (2014)
The myelodysplastic syndrome-comorbidity index provides additional prognostic information on patients stratified according to the revised international prognostic scoring system
Esther Zipperer et al.
HAEMATOLOGICA (2014)
Relationship of different platelet response criteria and patient outcomes in a romiplostim myelodysplastic syndromes trial
U. Platzbecker et al.
LEUKEMIA (2014)
Age-Related Clonal Hematopoiesis Associated with Adverse Outcomes
Siddhartha Jaiswal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
When is iron overload deleterious, and when and how should iron chelation therapy be administered in myelodysplastic syndromes?
David P. Steensma et al.
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2013)
Clinical Presentation, Diagnosis, and Prognosis of Myelodysplastic Syndromes
James M. Foran et al.
AMERICAN JOURNAL OF MEDICINE (2012)
Revised International Prognostic Scoring System for Myelodysplastic Syndromes
Peter L. Greenberg et al.
BLOOD (2012)
A phase 2 randomized multicenter study of 2 extended dosing schedules of oral ezatiostat in low to intermediate-1 risk myelodysplastic syndrome
Azra Raza et al.
CANCER (2012)
Association of anemia with worsened activities of daily living and health-related quality of life scores derived from the Minimum Data Set in long-term care residents
Robert A. Bailey et al.
HEALTH AND QUALITY OF LIFE OUTCOMES (2012)
The clinical, quality of life, and economic consequences of chronic anemia and transfusion support in patients with myelodysplastic syndromes
Uwe Platzbecker et al.
LEUKEMIA RESEARCH (2012)
Patterns of blood product use among patients with myelodysplastic syndrome
S. D. Ramsey et al.
VOX SANGUINIS (2012)
Implications of discrepancy in morphologic diagnosis of myelodysplastic syndrome between referral and tertiary care centers
Kiran Naqvi et al.
BLOOD (2011)
Epidemiology, Natural History, and Practice Patterns of Patients with Myelodysplastic Syndromes in 2010
Mikkael A. Sekeres
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2011)
What are RBC-transfusion-dependence and -independence?
R. P. Gale et al.
LEUKEMIA RESEARCH (2011)
Clinical Effect of Point Mutations in Myelodysplastic Syndromes
Rafael Bejar et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Safety and Efficacy of Romiplostim in Patients With Lower-Risk Myelodysplastic Syndrome and Thrombocytopenia
Hagop Kantarjian et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Multicenter Study of Decitabine Administered Daily for 5 Days Every 4 Weeks to Adults With Myelodysplastic Syndromes: The Alternative Dosing for Outpatient Treatment (ADOPT) Trial
David P. Steensma et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study
Pierre Fenaux et al.
LANCET ONCOLOGY (2009)
Myelodysplasia paranoia: Iron as the new radon
David P. Steensma
LEUKEMIA RESEARCH (2009)
Phase 2, single-arm trial to evaluate the effectiveness of darbepoetin alfa for correcting anaemia in patients with myelodysplastic syndromes
Janice Gabrilove et al.
BRITISH JOURNAL OF HAEMATOLOGY (2008)
Characteristics of US Patients with Myelodysplastic Syndromes: Results of Six Cross-sectional Physician Surveys
Mikkael A. Sekeres et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2008)
Common troublesome symptoms and their impact on quality of life in patients with myelodysplastic syndromes (MDS): Results of a large internet-based survey
David P. Steensma et al.
LEUKEMIA RESEARCH (2008)
The incidence and impact of thrombocytopenia in myelodysplastic syndromes
Hagop Kantarjian et al.
CANCER (2007)
Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion
Alan List et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia
Bruce D. Cheson et al.
BLOOD (2006)
Decitabine improves patient outcomes in myelodysplastic syndromes - Resuits of a Phase III randomized study
H Kantarjian et al.
CANCER (2006)
Health, economic, and quality-of-life effects of erythropoietin and granulocyte colony-stimulating factor for the treatment of myelodysplastic syndromes:: a randomized, controlled trial
N Casadevall et al.
BLOOD (2004)
分享论文
